Generic Lynparza Availability
Last updated on Jan 11, 2023.
Lynparza is a brand name of olaparib, approved by the FDA in the following formulation(s):
LYNPARZA (olaparib - capsule;oral)
-
Manufacturer: ASTRAZENECA
Approval date: December 19, 2014
Strength(s): 50MG (discontinued) [RLD]
LYNPARZA (olaparib - tablet;oral)
-
Manufacturer: ASTRAZENECA
Approval date: August 17, 2017
Strength(s): 100MG [RLD], 150MG [RLD]
Has a generic version of Lynparza been approved?
No. There is currently no therapeutically equivalent version of Lynparza available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lynparza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Phthalazinone derivatives
Patent 7,151,102
Issued: December 19, 2006
Inventor(s): Martin; Niall Morrison Barr & Smith; Graeme Cameron Murray & White; Charles Richard & Newton; Roger Frank & Douglas; Diane Gillian & Eversley; Penny Jane & Vile; Julia
Assignee(s): Kudos Pharmaceuticals Limited Maybridge PLCA method of treatment of a disease of the human or animal body mediated by PARP comprising administering to such a subject a therapeutically effective amount of a compound of formula: or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein: A and B together represent an optionally substituted, fused aromatic ring; RC is represented by —L—RL, where L is of formula: —(CH2)n1-Qn2-(CH2)n3— wherein n1, n2 and n3 are each selected from 0, 1, 2 and 3, the sum of n1, n2 and n3 is 1, 2 or 3 and Q is selected from O, S, NH, C(═O) or —CR1R2—, where R1 and R2 are independently selected from hydrogen, halogen or optionally substituted C1-7 alkyl, or may together with the carbon atom to which they are attached form a C3-7 cyclic alkyl group, which may be saturated (a C3-7 cycloalkyl group) or unsaturated (a C3-7 cycloalkenyl group), or one of R1 and R2 may be attached to an atom in RL to form an unsaturated C3-7 cycloalkenyl group which comprises the carbon atoms to which R1 and R2 are attached in Q, —(CH2)n3— (if present) and part of RL; and RL is optionally substituted C5-20 aryl; and RN is selected from hydrogen, optionally substituted C1-7 alkyl, C3-20 heterocyclyl, and C5-20 aryl, hydroxy, ether, nitro, amino, amido, thiol, thioether, sulfoxide and sulfone.
Patent expiration dates:
- April 29, 2022✓✓
- April 29, 2022
-
Phthalazinone derivatives
Patent 7,449,464
Issued: November 11, 2008
Inventor(s): Martin; Niall Morrison Barr & Smith; Graeme Cameron & Jackson; Stephen Philip & Loh; Vincent Junior M & Cockcroft; Xiao-Ling Fan & Matthews; Ian Timothy Williams & Menear; Keith Allan & Kerrigan; Frank & Ashworth; Alan
Assignee(s): Kudos Pharmaceuticals Limited Maybridge LimitedCompounds of the formula (I): wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X=NRX then n is 1 or 2 and if X=CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RY is selected from H, hydroxy, amino; or RX and RY may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are both hydrogen, or when X is CRXRY, RC1, RC2, RX and RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R1 is selected from H and halo.
Patent expiration dates:
- October 11, 2024✓✓
- October 11, 2024
-
Phthalazinone derivatives
Patent 7,981,889
Issued: July 19, 2011
Inventor(s): Barr Martin; Niall Morrison & Smith; Graeme Cameron & Jackson; Stephen Philip & Loh; Vincent Junior M & Cockcroft; Xiao-Ling Fan & Williams Matthews; Ian Timothy & Menear; Keith Allan & Kerrigan; Frank & Ashworth; Alan
Assignee(s): Kudos Pharmaceuticals Limited Maybridge LimitedCompounds of the formula (I): wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X═NRX then n is 1 or 2 and if X═CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RY is selected from H, hydroxy, amino; or RX and RY may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are both hydrogen, or when X is CRXRY, RC1, RC2, RX and RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R1 is selected from H and halo.
Patent expiration dates:
- October 11, 2024✓✓
- October 11, 2024
-
DNA damage repair inhibitors for the treatment of cancer
Patent 8,071,579
Issued: December 6, 2011
Inventor(s): Ashworth; Alan & Jackson; Stephen & Martin; Niall & Smith; Graeme
Assignee(s): The Institute of Cancer Research: Royal Cancer Hospital Kudos Pharmaceuticals LimitedThe present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.
Patent expiration dates:
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027
-
DNA damage repair inhibitors for treatment of cancer
Patent 8,143,241
Issued: March 27, 2012
Inventor(s): Ashworth; Alan & Jackson; Stephen & Martin; Niall & Smith; Graeme & O'Connor; Mark
Assignee(s): Kudos Pharmaceuticals Limited The Institute of Cancer ResearchThe present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.
Patent expiration dates:
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027✓
- August 12, 2027
-
Phthalazinone derivative
Patent 8,247,416
Issued: August 21, 2012
Inventor(s): Menear; Keith Allan & Ottridge; Anthony Peter & Londesbrough; Derek John & Hallett; Michael Raymond & Mulholland; Keith Raymond & Pittam; John David & Laffan; David Dermot Patrick & Ashworth; Ian Woodward & Jones; Martin Francis & Cherryman; Janette Helen
Assignee(s): Kudos Pharmaceuticals Limited4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline Form A.
Patent expiration dates:
- September 24, 2028✓
- September 24, 2028
-
Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
Patent 8,475,842
Issued: July 2, 2013
Assignee(s): Astrazeneca ABThe present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1 -carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.
Patent expiration dates:
- December 31, 2029✓
- December 31, 2029
-
Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
Patent 8,859,562
Issued: October 14, 2014
Assignee(s): The University of SheffieldThe present invention relates to the use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination.
Patent expiration dates:
- August 4, 2031✓
- August 4, 2031✓
- August 4, 2031✓
- August 4, 2031✓
- August 4, 2031✓
- August 4, 2031✓
- August 4, 2031✓
- August 4, 2031✓
- August 4, 2031✓
- August 4, 2031✓
- August 4, 2031✓
- August 4, 2031✓
- August 4, 2031✓
- August 4, 2031✓
- August 4, 2031✓
- August 4, 2031✓
- August 4, 2031
-
Phthalazinone derivatives
Patent 8,912,187
Issued: December 16, 2014
Assignee(s): Kudos Pharmaceuticals LimitedCompounds of the formula (I): wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X═NRX then n is 1 or 2 and if X═CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RY is selected from H, hydroxy, amino; or RX and RY may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are both hydrogen, or when X is CRXRY, RC1, RC2, RX and RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R1 is selected from H and halo.
Patent expiration dates:
- March 12, 2024✓
- March 12, 2024✓
- March 12, 2024✓
- March 12, 2024✓
- March 12, 2024✓
- March 12, 2024✓
- March 12, 2024✓
- March 12, 2024✓
- March 12, 2024✓
- March 12, 2024✓
- March 12, 2024✓
- March 12, 2024✓
- March 12, 2024
-
Phthalazinone derivatives
Patent 9,169,235
Issued: October 27, 2015
Assignee(s): KUDOS PHARMACEUTICALS LIMITEDCompounds of the formula (I): wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X═NRX then n is 1 or 2 and if X═CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RY is selected from H, hydroxy, amino; or RX and RY may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are both hydrogen, or when X is CRXRY, RC1, RC2, RX and RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R1 is selected from H and halo.
Patent expiration dates:
- March 12, 2024✓
- March 12, 2024✓
- March 12, 2024
-
Phthalazinone derivatives
Patent 9,566,276
Issued: February 14, 2017
Assignee(s): KUDOS PHARMACEUTICALS LIMITEDCompounds of the formula (I): wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X═NRX then n is 1 or 2 and if X═CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RY is selected from H, hydroxy, amino; or RX and RY may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1and RC2 are both hydrogen, or when X is CRXRY, RC1, RC2, RX and RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R1 is selected from H and halo.
Patent expiration dates:
- March 12, 2024✓
- March 12, 2024
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- December 27, 2022 - MAINTENANCE TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GBRCAM METASTATIC PANCREATIC ADENOCARCINOMA WHOSE DISEASE HAS NOT PROGRESSED ON AT LEAST 16 WEEKS OF A FIRST-LINE PLATINUM-BASED CHEMOTHERAPY REGIMEN
- May 8, 2023 - W/BEVACIZUMAB FOR MAINTENANCE TX OF ADULTS W/ADV. EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CA IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMO & CA ASSOCIATED W/ HOMOLOGOUS RECOMBINATION DEFICIENCY POSITIVE STATUS
- May 19, 2023 - TX OF ADULT PTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC HOMOLOGOUS RECOMBINATION REPAIR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PROGRESSED FOLLOWING PRIOR TREATMENT WITH ENZALUTAMIDE OR ABIRATERONE
- August 17, 2024 - MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
- August 17, 2024 - TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY
- March 11, 2025 - FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GBRCA MUTATED HER2-NEGATIVE HIGH-RISK EARLY BREAST CANCER WHO HAVE PREVIOUSLY BEEN TREATED WITH NEOADJUVANT OR ADJUVANT CHEMOTHERAPY
- December 19, 2025 - MAINTENANCE TREATMENT OF ADULTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC BRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY
- December 27, 2026 - MAINTENANCE TX OF ADULTS W/ DELETERIOUS OR SUSPECTED DELETERIOUS GBRCAM METASTATIC PANCREATIC ADENOCARCINOMA WHOSE DZ HAS NOT PROGRESSED ON >=16WKS OF 1ST LINE PLATINUM BASED CHEMO REGIMEN. SELECT PTS FOR THERAPY BASED ON APPROVED COMPANION DIAGNOSTIC
- May 8, 2027 - W/ BEVACIZUMAB FOR MAINT TX OF ADULTS W/ ADV EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CA IN COMPLETE OR PARTIAL RESPONSE TO 1ST LINE PT BASED CHEMO & WHOSE CA IS ASSOC W/ HOMOLOGOUS RECOMB DEF + STATUS DEFINED BY GENOMIC INSTABILITY
More about Lynparza (olaparib)
- Check interactions
- Pricing & coupons
- Reviews (14)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: PARP inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.